Literature DB >> 17532671

Pioglitazone lowers blood pressure in hypertensive patients with type 2 diabetes mellitus : an open, multicentre, observational study.

Thomas Konrad1, Georg Lübben, Christine Franzen.   

Abstract

Entities:  

Year:  2005        PMID： 17532671     DOI： 10.2165/00044011-200525050-00006

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  21 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

2.  Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.

Authors:  S Füllert; F Schneider; E Haak; H Rau; K Badenhoop; G Lübben; K-H Usadel; T Konrad
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

3.  Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state.

Authors:  S M Haffner; L Mykkänen; A Festa; J P Burke; M P Stern
Journal:  Circulation       Date:  2000-03-07       Impact factor: 29.690

4.  Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus.

Authors:  Burkhard Göke
Journal:  Treat Endocrinol       Date:  2002

5.  Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus.

Authors:  B H Sung; J L Izzo; P Dandona; M F Wilson
Journal:  Hypertension       Date:  1999-07       Impact factor: 10.190

6.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

Authors:  R C Turner; H Millns; H A Neil; I M Stratton; S E Manley; D R Matthews; R R Holman
Journal:  BMJ       Date:  1998-03-14

7.  Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus.

Authors:  Pietro Gerber; Georg Lübben; Sabine Heusler; Ayako Dodo
Journal:  Curr Med Res Opin       Date:  2003       Impact factor: 2.580

Review 8.  Effects of the thiazolidinediones on cardiovascular risk factors.

Authors:  Lucia Gilling; Pitiporn Suwattee; Cyrus DeSouza; Sunil Asnani; Vivian Fonseca
Journal:  Am J Cardiovasc Drugs       Date:  2002       Impact factor: 3.571

Review 9.  Metabolic and additional vascular effects of thiazolidinediones.

Authors:  Fabrice M A C Martens; Frank L J Visseren; Jacinthe Lemay; Eelco J P de Koning; Ton J Rabelink
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.

Authors:  S MacMahon; R Peto; J Cutler; R Collins; P Sorlie; J Neaton; R Abbott; J Godwin; A Dyer; J Stamler
Journal:  Lancet       Date:  1990-03-31       Impact factor: 79.321
View more
  2 in total

1.  Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice.

Authors:  Mohan R Dasu; Samuel Park; Sridevi Devaraj; Ishwarlal Jialal
Journal:  Endocrinology       Date:  2009-04-23       Impact factor: 4.736

2.  SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.

Authors:  Muhammad Abdul-Ghani; Stefano Del Prato; Robert Chilton; Ralph A DeFronzo
Journal:  Diabetes Care       Date:  2016-05       Impact factor: 19.112
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.